DNA testing revolutionizes metastatic castration-resistant prostate cancer prognosis, improving patient outcomes with faster ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment ...

Guardant Health's heavy investment in R&D, growing from $10.9 million in 2016 to $365.1 million in 2023, indicates a focus on future growth. Learn more on GH stock here.

The POLAR genomic signature can help predict the patients with early breast cancer who may benefit from adjuvant radiotherapy ...

Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen ( NCT06564844 ). Assay performance was ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.